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Objectives. This study sought to test whether the physiologic
advantage of a prolonged dobutamine stage during stress echo-
cardiography can be effectively combined with a clinically practi-
cal infusion protocol.
Background. Dobutamine has a half-life of 2 min and requires
up to 10 min to achieve steady state. Despite these known
pharmacodynamics, dobutamine stress echocardiography is rou-
tinely performed by advancing doses at 3-min intervals. Canine
studies have shown that dobutamine stress echocardiography end
points will occur at a lower dose if each stage is prolonged, but
these findings have yet to be used in the clinical setting.
Methods. The standard 3-min dobutamine dose stage during
stress echocardiography was modified by extending the peak dose
(40 mg/kg body weight per min) for an additional 2 min. Consec-
utive patients underwent this modified protocol to test whether
the requirement for atropine could be reduced. According to this
modified protocol, if a dobutamine stress echocardiographic end
point (85% of maximal predicted heart rate, new wall motion
abnormalities, hypotension, arrhythmia or intolerable symptoms)
was not reached at 3 min of the peak dose, this dose was prolonged
for an additional 2 min. If a dobutamine stress echocardiographic
end point was still not attained, atropine (up to 1.0 mg intrave-
nously) was administered.
Results. The study included 84 patients, 22 of whom (26.2%)
achieved a dobutamine stress echocardiographic end point using
the standard 3-min stage. Of the 62 patients who did not reach an
end point in the initial 3 min of peak dobutamine dose, the
additional 2 min of dobutamine increased heart rate (from 99.6 6
23.8 to 107.2 6 23.2 beats/min, p < 0.01) and allowed 20 patients
(32.3%, p < 0.01) to attain an end point. Of the remaining 42
patients, 23 never achieved a stress echocardiographic end point,
despite 1.0 mg of atropine. One patient developed supraventricu-
lar tachycardia during the additional 2 min of dobutamine, and
one developed nonsustained ventricular tachycardia after receiv-
ing atropine.
Conclusions. These data demonstrate that a significant number
of patients (32%) who do not reach a dobutamine stress echocar-
diographic end point with the standard protocol can safely attain
an end point solely by extending the duration of the peak dose.
Adoption of this strategy may reduce the need for supplemental
atropine and its potential adverse effects.
(J Am Coll Cardiol 1997;29:526–30)
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Despite the wide acceptance of dobutamine stress echocardi-
ography as a noninvasive method for detecting myocardial
ischemia, a lack of protocol standardization persists. In the
United States, dobutamine protocols most commonly use
3-min stages of increasing dobutamine doses. However, dobut-
amine stage duration was adopted from the standard Bruce
protocol used in exercise treadmill tests without consideration
of dobutamine pharmokinetics (1,2). The pharmacologic half-
life of dobutamine is 2 min, with steady state not obtained for
up to 10 min (3,4). Thus, 3-min dobutamine stage results in
advancing the dose before achieving steady state.
Using a canine model, we previously showed (5) that
prolonging the duration of infusion of each dobutamine dose
stage will result in a greater hemodynamic effect at lower
doses, which may improve test accuracy without requiring
additional pharmacologic agents or higher dobutamine doses.
In addition, dobutamine stress echocardiographic end points
were achieved at a lower dobutamine dose with prolonged
stages (5). The limitation of 3-min stages has been recognized
clinically in the assessment of myocardial viability, where low
dose dobutamine is typically extended for at least 5 min (6–8).
Although a logical approach to dobutamine stress testing
based on dobutamine pharmacodynamics would be to extend
the duration of each dobutamine stage to 10 min, such a long
test is not practical in the clinical setting. In an attempt to
balance drug effect with a test design of practical duration, we
hypothesized that the beneficial effects of a prolonged stage
could be attained by extending the peak dobutamine dose. We
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therefore chose to test whether modifying the 40-mg/kg body
weight per min dobutamine dose by extending it an additional
2 min would result in a greater proportion of patients reaching
an end point while reducing the need for atropine.
Methods
Patient selection. Eighty-four consecutive patients present-
ing for diagnostic dobutamine stress echocardiography to the
echocardiography laboratories at the Massachusetts General
Hospital (n 5 54) and Georgetown University Hospital (n 5
30) without exclusion criteria were enrolled in the study.
Exclusion criteria included a myocardial infarction within 3
days, unstable rest angina requiring intravenous nitroglycerin,
recent ventricular tachycardia, uncontrolled atrial fibrillation,
Wolff-Parkinson-White syndrome or contraindication to atro-
pine. Concurrent medications were continued at the discretion
of the referring physician. Whenever possible, beta-adrenergic
antagonists were held for at least 24 h before stress echocar-
diography. All patients gave written informed consent to
participate in the stress echocardiographic protocol.
Modified dobutamine protocol. All dobutamine stress tests
were performed under continuous 12-lead electrocardio-
graphic (ECG) and noninvasive blood pressure monitoring.
After obtaining rest heart rate, blood pressure and left ven-
tricular two-dimensional echocardiographic images, the dobut-
amine infusion was initiated. Dobutamine was infused in 3-min
stages with increasing doses of 5, 10, 20, 30 and 40 mg/kg per
min. At the end of each dose, standard two-dimensional
echocardiographic images of the left ventricle, a 12-lead ECG
and blood pressure were obtained. End points for termination
of the dobutamine infusion included new wall motion abnor-
malities, 85% of maximal predicted heart rate, sustained
arrhythmias, intolerable symptoms or hypotension (decrease in
systolic blood pressure .20 mm Hg). Echocardiographic im-
ages were recorded onto 0.5-in. VHS videotape for subsequent
analysis. In addition, individual cardiac cycles of four left
ventricular views (parasternal long and short axis and apical
four and two chamber) at baseline, low dose and peak stress
were digitized in a standard quad screen format that allowed
on-line side by side comparison. The on-line assessment of
wall motion and hemodynamic response to dobutamine was
made independently by experienced echocardiographers
(N.J.W., M.H.P.).
If an end point was not obtained at the end of the 3-min
stage at 40 mg/kg per min of dobutamine, then the ECG,
hemodynamic and echocardiographic images were recorded,
and the dobutamine infusion was continued for an additional
2 min. Hemodynamic, ECG and left ventricular echocardio-
graphic images were recorded again, and if the patient still did
not reach a dobutamine stress echocardiographic end point,
atropine (up to 1.0 mg) was administered intravenously. No
further pharmacologic stress beyond dobutamine (40 mg/kg per
min for a total cumulative dose of 395 mg/kg) and atropine
(1.0 mg total) was administered.
Statistical analysis. Results are expressed as mean value6
SD. A paired, two-tailed Student t test was used to compare
the hemodynamic responses with the 3- and 5-min dobutamine
infusion protocols at 40 mg/kg per min. The proportion of
patients attaining a dobutamine stress echocardiographic end
point, thus avoiding the need for atropine because of the
prolonged infusion protocol, was assessed with a Fisher exact
test. Only p values #0.05 were considered significant.
Results
Patients. Eighty-four patients (55 men, 29 women; mean
age 61.3 6 14.4 years, range 21 to 83) were enrolled in the
study. Before the stress test, rest heart rate was 74 6 13
beats/min and systolic blood pressure 142 6 26 mm Hg.
Sixteen (19%) of 84 patients were taking beta-adrenergic
blocking medication, which was present for 12 to 24 h in 19
patients (23%).
Of the 84 patients enrolled, 11 (13%) reached a dobut-
amine stress echocardiographic end point before the 40 mg/kg
per min dose (n5 3 at 20 mg/kg per min; n5 8 at 30 mg/kg per
min). Sixty-two of the 73 patients who reached 40 mg/kg per
min underwent a prolonged infusion because they failed to
reach an end point with the standard 3-min stage. As displayed
in Table 1, heart rate increased from 100 6 24 to 107 6 23
beats/min (p, 0.01) with the longer peak dose stage, but blood
pressure did not change (154 6 33 vs. 149 6 33 beats/min, p 5
NS). The additional 2 min of dobutamine allowed 20 (32.3%)
of the 62 patients to reach an end point and thus avoid
atropine (p , 0.01). The end points reached included 85% of
maximal predicted heart rate (n 5 9), new wall motion
abnormalities (n 5 6), hypotension (n 5 2), intractable
symptoms (palpitations [n 5 1], “nervousness” [n 5 1]) and
development of supraventricular tachycardia (n 5 1).
Among the 42 patients who did not reach an end point with
the prolonged peak dobutamine dose, all received atropine
(0.74 6 0.29 mg), with a resulting heart rate increase of 27.7 6
19.9 beats/min (p , 0.001). Of these patients, 16 (38.1%)
achieved target heart rate, 1 developed a new wall motion
abnormality, 1 complained of intolerable palpitations, and 1
developed nonsustained ventricular tachycardia with atropine.
Therefore, a total of 19 (45.2%) of 42 patients who did not
reach a test end point with the prolonged dobutamine infusion
did obtain an end point with atropine. Among the 42 patients
Table 1. Hemodynamic Variables at Peak Dobutamine Stages
Dobutamine (40 mg/kg per min)
Atropine*
(n 5 42)
3-min Duration
(n 5 73)
5-min Duration
(n 5 62)
HR (beats/min) 100 6 24 107 6 23† 129 6 19‡
SBP (mm Hg) 1546 33 149 6 33 163 6 37
*After administration of atropine up to a maximum of 1.0 mg if no end point
was obtained with a lower dose. †p , 0.01 versus heart rate (HR) at 3-min
duration. ‡p , 0.001 versus heart rate at 5-min duration. Data presented are
mean value 6 SD. SBP 5 systolic blood pressure.
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who required atropine, 54.8% (23 of 42) never achieved a test
end point despite administration of the maximal atropine dose
(1.0 mg). As displayed in Table 2, the end points responsible
for test termination at each of the peak stages were similar for
standard duration dobutamine, prolonged peak dobutamine or
atropine. Of the nine patients whose test was positive due to a
new wall motion abnormality, eight (89%) developed this end
point without the need for atropine. Figure 1 is a flow diagram
that summarizes the response of all patients enrolled in the
study and the dose at which an end point was achieved.
For those patients who did not reach an end point at 3 min
of 40 mg/kg per min, rest heart rate, age and gender were not
predictive (p 5 NS) of prolonged infusion effectiveness or
atropine effectiveness. Similarly, concurrent beta-adrenergic
blocking medication was not associated with the final dobut-
amine dose, ability of a prolonged infusion to reach an end
point, or ability of atropine to reach an end point. This may be
due to the small number of patients taking concurrent beta-
blocker therapy (n5 16). Higher heart rate at the end of 3 min
of the peak dobutamine dose was the only variable predictive
of a prolonged infusion success (108 6 12 vs. 87 6 19
beats/min, p , 0.001).
Discussion
Dobutamine pharmocodynamics requires up to 10 min to
reach steady state and exert its full hemodynamic effect (3,4).
Therefore, stress echocardiography performed with 3-min
stages reach peak physiologic stimulation through a series of
transient escalating doses of dobutamine that summate with-
out ever reaching steady state, and the full effect of any one
dose of dobutamine is not attained before the elevation of the
dobutamine dose to the next level. Thus, prolonging the stage
duration, even by a few minutes, would allow the dobutamine
dose to approach its potential physiologic effect. This effect has
been previously confirmed in a canine model (5) in which a
5-min dobutamine stage allowed dobutamine stress echocar-
diographic end points to be attained at a lower dobutamine
dose than 3-min stages (5). In the purist sense, dobutamine
stress echocardiographic protocols would use 10-min stages so
that the full potential of each dobutamine dose could be
realized before advancing to the next dose, but the duration
of such a test must be balanced with clinical practicality.
The approach in this study, as an initial step, was to extend the
40 mg/kg per min dobutamine dose to gain more of the
physiologic effects of the peak dose without excessively pro-
longing the protocol. This simple modification resulted in an
additional 32% of the patients reaching a dobutamine stress
echocardiographic end point, thus avoiding the need for
atropine.
Value and limitation of dobutamine stress testing. Phar-
macologic stress testing has become a routine diagnostic tool in
clinical practice because of the high proportion of patients with
suspected coronary disease who are unable to adequately
exercise. Because of the low sensitivity of ECG changes with
pharmacologic stress (9,10), imaging is required. Echocardiog-
raphy in conjunction with dobutamine has a high sensitivity
and specificity for the diagnosis of occlusive coronary disease,
application in a wide range of patients, easy integration into
current echocardiography laboratories and comparable safety
to other forms of stress testing (1,11,12). However, the rapid
Table 2. End Point Responsible for Test Termination at Peak
Dobutamine Stages
Dobutamine (40 mg/kg per min)
Atropine*3-min Duration 5-min Duration
Total reaching end point 22/84 20/62 19/42
85% max pred HR 19 9 16
New WMA 2 6 1
Sxs/hypotension 1 4 1
Adverse effects 0 1 1
*After administration of atropine up to a maximum of 1.0 mg if no end point
was obtained with a lower dose. Data presented are number of patients. max
pred HR 5 maximal predicted heart rate; WMA 5 wall motion abnormality;
Sxs 5 intolerable symptoms.
Figure 1. Flow diagram summarizing the response of all patients
enrolled in the study and the dose at which a dobutamine stress
echocardiographic end point was achieved. Of the 62 patients that
required 40 mg/kg per min using the standard 3-min stage and still did
not reach an end point, 20 (32.3%) were able to obtain an end point by
extending the 40-mg/kg per min stage an additional 2 min.
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deployment of dobutamine stress echocardiography has re-
sulted in the widespread use of an infusion protocol that is
based on exercise physiology rather than dobutamine pharma-
codynamics. Consequently, dobutamine stress protocols re-
quire more time than most exercise protocols, may not reach a
predetermined heart rate without the addition of a supplemen-
tal pharmacologic agent, require a prolonged period of recov-
ery and might not be as effective in the presence of concomi-
tant beta-adrenergic antagonists (13,14).
Advantages of modified dobutamine protocol. The positive
inotropic and chronotropic stimulation from dobutamine,
which increases myocardial oxygen demand, is coupled
through the same beta1-adrenoceptor (15,16). Because the
physiologic response to dobutamine is linearly related to
plasma dobutamine levels (17), prolonging dobutamine infu-
sions results in a greater myocardial oxygen demand by in-
creasing the dobutamine plasma level. This finding has been
confirmed by Poldermans et al. (18) in an initial study mea-
suring the catecholamine response to a prolonged low dose
dobutamine infusion that demonstrated a progressive increase
in heart rate during the first 9 min. Likewise, the increase in
heart rate seen in our study is probably due to an increased
plasma dobutamine level stimulating a greater proportion of
the adrenoreceptors. When the adrenoreceptors are occupied
by adrenergic antagonists, the response to dobutamine will be
dependent on the level of beta-blockade, dobutamine plasma
levels and the underlying catecholamine state/left ventricular
function of the patient (19,20). This represents another clinical
setting in which prolonging the dobutamine infusion would
provide higher plasma levels of dobutamine to potentially
overcome the beta-blockade. Only a minority of patients in this
study were receiving beta-blockade therapy, and they consti-
tute a heterogenous group with varying levels of beta-blockade
and underlying catecholamine stimulation. A controlled study
measuring beta-receptor activity before dobutamine infusion
would further elucidate the value of prolonging peak stage
duration in these patients.
Extending the final dobutamine dose is a practical alterna-
tive to the standard 3-min stage. This modified protocol allows
dobutamine stress echocardiography to start at conventional
low doses and step up at a rapid rate to peak dose while
providing a means to avoid atropine in some patients. During
the present protocol, three patients were not entered into the
study because they were not candidates for atropine due to
preexisting medical conditions. In all three patients, target
heart rate was achieved by extending the 40-mg/kg per min
dose: But is the avoidance of atropine necessary or even
beneficial? Dobutamine–atropine stress testing is widely used,
with a low incidence of severe adverse effects (1). Atropine
reliably increases heart rate and improves the sensitivity of
dobutamine stress echocardiography, especially in patients
receiving beta-blockade therapy (13). The goal of stress echo-
cardiography is to detect inducible ischemia by increasing
myocardial oxygen demand. Atropine increases oxygen de-
mand by increasing heart rate but has a minimal effect on the
other determinants of myocardial oxygen, such as left ventric-
ular contractility and wall tension (21). It is therefore not
surprising that the recent study by Ling et al. (22), investigating
the incremental value of atropine during dobutamine stress
echocardiography, demonstrated only a modest influence of
atropine on overall diagnostic sensitivity. Because dobutamine
provides both inotropic and chronotropic stimulation, a
greater increase in myocardial oxygen demand is expected for
a given increase in heart rate produced by dobutamine than by
atropine. This increased oxygen demand could improve sensi-
tivity by inducing ischemia in the setting of a mild obstruction
to flow, which may have otherwise gone undetected, or pro-
duce ischemia at an earlier stage for an equivalent stenosis.
Prolonged dobutamine stages may therefore improve sensitiv-
ity over the standard dobutamine–atropine protocol. This
improved sensitivity is supported by the finding that six (67%)
of nine patients with inducible wall motion abnormalities were
detected by the prolonged dobutamine arm. In fact, atropine
only induced a new regional wall motion in 1 (2%) of 42
patients who did not respond to the prolonged dobutamine
infusion. In concordance with previous studies, the majority of
patients with obstructive coronary stenoses are detected before
the addition of atropine (22). Atropine after a prolonged
dobutamine stage may solely increase heart rate to the target
rate (in 16 of 42 patients), with a marginal contribution to the
primary purpose of dobutamine stress echocardiography—
detection of significant coronary stenosis. Further investigation
will be necessary to determine the risk/benefit ratio of prolong-
ing the peak dobutamine stage.
Application of modified dobutamine protocol. Clinical
identification of patients who would benefit from the pro-
longed peak dobutamine infusion may be difficult. Clearly,
patients who do not reach an adequate heart rate with the
current dobutamine stress echocardiographic protocol and are
not candidates for atropine (because of narrow-angle glau-
coma, myasthenia gravis, obstructive uropathy or obstructive
gastrointestinal disorder) would benefit from the prolonged
dobutamine infusion. Fortunately, patients who fall into this
category are rare. It would be ideal to prospectively identify
patients in which prolonged dobutamine infusion will be
successful. Other preliminary reports (23) suggest that heart
rate at the 20 mg/kg per min stage may be predictive of
chronotropic incompetence at the peak dobutamine stage. In
our study, only heart rate at the end of 3 min at 40 mg/kg per
min was predictive of attaining target heart rate with the
prolonged infusion. A reasonable approach would therefore be
to select those patients who are close to, but not at, target heart
rate at the end of the current dobutamine stress echocardio-
graphic protocol for additional dobutamine rather than atro-
pine. Because there were no pretest characteristics that were
able to predict who would respond to the prolonged infusion,
a larger study investigating the utility of prolonged dobutamine
infusions in selected patient groups is necessary to clarify its
clinical role.
Limitations of the study. The small sample size of the
present study precludes adequate analysis of clinically relevant
subgroups, such as those receiving concomitant beta-blocker
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therapy. Beta-antagonists attenuate and delay the dobutamine
response (14). Prolonged dobutamine infusion provides a
higher serum level of beta-agonists that should overcome the
beta-blockade and counteract the attenuated response. Thus,
patients taking beta-blockers should especially benefit from the
modified protocol; however, the small number of patients (n5
16) receiving varying levels of beta-blocker therapy in this
study precludes adequate analysis.
The results of any investigation of a diagnostic test depend
on the patients studied. In our study, the majority of patients
were men between 50 and 70 years old, with a moderate pretest
likelihood of coronary disease. Our results would apply to this
patient cohort but need to be further assessed before applica-
tion in patients with a different pretest likelihood of disease.
The present study was designed to test the feasibility of a
modified dobutamine infusion protocol that used an extended
peak dose, but it does not provide a head to head comparison
of different protocols (24). Thus, future studies are necessary
to determine how the extended peak infusion protocol com-
pares with standard dobutamine and dobutamine–atropine
protocols.
Conclusions. We showed that a simple modification of the
dobutamine stress infusion protocol is feasible and can in-
crease test sensitivity and decrease the need for atropine.
Further evaluation of extended dobutamine infusions will be
necessary to determine the optimal protocol for stress echo-
cardiography.
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